Reolysin is an oncolytic virus commercialized by Oncolytics Biotech, with a leading Phase II program in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer).
To perform comprehensive surveillance for healthcare-associated infections and epidemiologically significant organisms and To create, implement, support, and sustain evidence-based interventions to ...